Alpha Thalassemia Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Alpha Thalassemia Market is segmented By Type of Disease (Transfusion-Dependent Alpha Thalassemia (TDT), Non-Transfusion Dependent Alpha Thalassemia (NTDT)), By Treatment ....
Alpha Thalassemia Market Size
Market Size in USD
CAGR9.10%
| Study Period | 2024 - 2031 |
| CAGR | 9.10% |
| Market Concentration | Medium |
| Major Players | Agios Pharmaceuticals, Novo Nordisk, Bristol-Myers Squibb, Forma Therapeutics, Silence Therapeutics |
please let us know !
Alpha Thalassemia Market Analysis
The Global Alpha Thalassemia market is estimated to be valued at USD 4.4 bn in 2024 and is expected to reach USD 9.1 bn by 2031, growing at a compound annual growth rate (CAGR) of 9.10% from 2024 to 2031. Alpha Thalassemia is a blood disorder caused by mutations in the HBA1 and HBA2 genes. The increasing prevalence of alpha-thalassemia disorders globally is expected to drive the growth of the market during the forecast period.
The market is witnessing positive growth owing to rising awareness about the disorder and its treatment options. Furthermore, new product developments to treat the underlying genetic abnormalities and enhanced screening programs help detect cases are contributing to the market expansion. However, the absence of symptomatic treatment options and lack of disease-modifying drugs are some of the challenges restraining the market growth.